ER、PR、HER-2、Ki-67在乳腺浸润性导管癌合并导管原位癌组织中的表达及意义

Expression condition analysis of ER,PR,HER-2 and ki-67 in the tissues of breast invasive ductal carcinoma complicated with ductal carcinoma in situ

目的:研究雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(HER-2)、Ki-67在乳腺浸润性导管癌合并导管原位癌患者组织中的表达情况。方法:2015年2月—2019年2月,乳腺浸润性导管癌合并导管原位癌患者200例,分别采用免疫组织化学法检测所有患者癌组织中ER、PR、HER-2、Ki-67的表达情况,并分析表达情况与患者病理参数之间的关系。结果:ER在TNMⅠ~Ⅱ级的乳腺浸润性导管癌合并导管原位癌组织中表达高于Ⅲ级患者(P<0.05)。PR和ki67在TNMⅠ~Ⅱ级的乳腺浸润性导管癌合并导管原位癌组织中表达均低于Ⅲ级患者(P<0.05)。HER-2在年龄、肿瘤直径、TNM分期、组织学分级以及淋巴结转移中的表达差异不明显(均P>0.05)。结论:检测ER、PR、HER-2、Ki-67表达水平,有利于评估乳腺浸润性导管癌合并导管原位癌患者的病情,为临床治疗方案的制定提供指导作用。

Objective:To investigate the expression of estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor-2(HER-2)and ki-67 in breast invasive ductal carcinoma with ductal carcinoma in situ.Methods:200 cases of invasive ductal carcinoma of breast complicated with ductal carcinoma in situ admitted to our hospital from February 2015 to February 2019 were selected as observation objects.The expressions of ER,PR,HER-2 and ki-67 in cancer tissues of all patients were detected by immunohistochemical method,and the relationship between the expressions of the above indicators and the pathological parameters of patients was analyzed.Results:ER level in histological grading forⅠ~Ⅱinfiltrating ductal carcinoma combined ductal carcinoma in situ tissue expression was higher than the histologic class forⅢpatients(P<0.05).PR in histological grading ofⅠ~Ⅱinfiltrating ductal carcinoma combined ductal carcinoma in situ tissue histologic classification expressed in less than a categoryⅢpatients(P<0.05).There was no significant difference in the expression of HER-2 in age,tumor diameter,TNM stage,histological grade and lymph node metastasis(all P>0.05).Ki-67 level in histological grading forⅠ~Ⅱinfiltrating ductal carcinoma combined ductal carcinoma in situ tissue histologic classification expressed in less than a categoryⅢpatients(P<0.05).Conclusion:The combined detection of the expressions of ER,PR,HER-2 and ki-67 is conducive to the evaluation of the condition of patients with invasive ductal carcinoma of breast combined with ductal carcinoma in situ,thus providing guidance for the formulation of clinical treatment plans.